Neva SGR

Neva SGR is the venture arm of Intesa Sanpaolo, Italy’s largest banking group, and operates from Turin with a mandate to deploy meaningful capital into European deep tech and healthcare companies that are scaling beyond their domestic market. The corporate venture structure means Neva can write larger checks and hold positions longer than most pure financial VCs, but it also means founders should expect a slightly more institutional process than at a typical early-stage firm. Healthcare focus areas include health IT, healthcare software, and AI/ML applied to clinical and operational settings.

The thesis is grounded in deep tech and infrastructure-oriented businesses, with healthcare appearing where software, cloud architecture, and machine learning intersect with medical workflows. Neva tends to look for companies with defensible technical moats, identifiable enterprise customers, and a clear path to scaling across multiple European markets or globally. Within healthcare, that bias plays out as a preference for B2B software platforms, AI tooling for providers and payers, and medical technology with a strong digital component over pure consumer wellness or single-market service businesses.

The firm participates from seed through Series C, with check sizes typically between $1M and $5M at entry and the ability to follow on through subsequent rounds. That stage flexibility is unusual and useful for founders who want a long-duration partner that will not pressure them into a premature exit. Geographically, Neva is most active in Italy and across continental Europe, with selective participation in companies operating internationally. Italian founders specifically benefit from Neva’s relationship with the Intesa Sanpaolo banking network, which provides commercial access into a substantial domestic enterprise customer base.

The team is structured as a professional investment organization with sector specialists, and decision-making goes through a formal investment committee. Founders should expect a more deliberate process than at a typical seed firm, but the trade-off is that the investment, once made, comes with the institutional credibility of one of Europe’s largest banks.

Post-investment, the most distinctive value Neva provides is access to Intesa Sanpaolo’s corporate and SME customer network, which can materially shorten enterprise sales cycles for healthcare software founders selling into Italian institutions. The firm also helps with subsequent fundraising, particularly when bringing in international growth-stage capital, and provides board-level guidance on European regulatory matters. Neva is less useful for founders who want a hands-on operational partner in the day-to-day or who are building purely consumer products without an enterprise wedge. The fit is strongest for healthcare AI and software companies with enterprise customers, defensible technology, and ambitions to operate across multiple European geographies. Founders considering Neva should plan for a process that values substance over speed and should bring a clear articulation of how Intesa’s distribution can accelerate their business.